Seasonal flu is a common infectious disease of the respiratory tract and is caused by the influenza virus. There are four kinds of influenza virus: influenza type A, B, C, and D.
The A and B types have gained huge interest in the medical community since they are the criminals for seasonal epidemics. At times, influenza A, like the A/Hong Kong/1/1968 (H3N2), and A/California/04/09 (H1N1), can even result in global pandemics.
Image Credit: Sino Biological Inc
Vaccination is considered the most effective method to avoid flu infection. Every year, various flu strains are chosen as vaccine candidates depending on surveillance data of the recent isolates and the performance of the vaccines from the earlier season.
Recently, the majority of the influenza vaccines are trivalent or quadrivalent, made of one H1N1, one H3N2, and either one or two type B viruses (Victoria lineage and Yamagata).
Image Credit: Sino Biological Inc
Sino Biological provides recombinant flu antigen products under its ProVir™ viral antigen collection. The product line includes Neuraminidase (NA), Hemagglutinin (HA) and Nucleoprotein (NP) proteins, from all WHO-recommended vaccine strains in the past few years. Such antigens could be utilized to examine vaccine-induced antibody response.
Sino Biological has also come up with a huge collection of monoclonal antibodies against the flu antigens. Such reagents can help streamline appropriate assay development.
Source: Sino Biological Inc
Year 2022-2023
| A/Victoria/2570/2019 (H1N1) |
| Recommended for Egg-based (quadrivalent,trivalent) Vaccine |
| HA: 40787-V08H, 40787-V08H1 |
| NA: 40785-V08B |
| NP: 40774-V08B |
| A/Wisconsin/588/2019 (H1N1) |
| Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine |
| HA: 40787-V08H, 40787-V08H1 |
| NA: 40785-V08B |
| NP: 40774-V08B |
| B/Phuket/3073/2013 |
| Recommended for Egg-based, Cell- or recombinant-based (quadrivalent) Vaccine |
| HA: 40498-V08B |
| NA: 40502-V07B |
| NP: 40500-V08B |
| A/Darwin/9/2021 (H3N2) |
| Recommended for Egg-based (quadrivalent, trivalent) Vaccine |
| HA: 40859-V08H, 40859-V08B |
| NA: 40860-V08B |
| NP: 40858-V08B |
| B/Austria/1359417/2021 (B/Victoria lineage) |
| Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine |
| HA: 40862-V08H, 40862-V08B |
| NA: 40863-V08B |
| NP: 40861-V08B |
| A/Darwin/6/2021 (H3N2) |
| Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine |
| HA: 40868-V08H, 40868-V08B |
| NA: 40869-V08B |
| NP: 40858-V08B |
Year 2021-2022
| A/Victoria/2570/2019 (H1N1) |
| Recommended for Egg-based (quadrivalent,trivalent) Vaccine |
| HA: 40787-V08H, 40787-V08H1 |
| NA: 40785-V08B |
| NP: 40774-V08B |
| A/Wisconsin/588/2019 (H1N1) |
| Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine |
| HA: 40787-V08H, 40787-V08H1 |
| NA: 40785-V08B |
| NP: 40774-V08B |
| B/Washington/02/2019 |
| Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine |
| HA: 40722-V08H |
| NA: 40790-V08B |
| NP: 40755-V08B |
| B/Phuket/3073/2013 |
| Recommended for Egg-based, Cell- or recombinant-based (quadrivalent) Vaccine |
| HA: 40498-V08B |
| NA: 40502-V07B |
| NP: 40500-V08B |
| A/Cambodia/E0826360/2020 (H3N2) |
| Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine |
| HA: 40789-V08H, 40789-V08H1 |
| NA: 40784-V08B |
| NP: 40778-V08B |
Learn More About Reagents for Influenza Vaccine Strains